Tiantian Biology and MorphoSys announced the completion of the first patient drug treatment in the TJ2101 clinical study

On January 26, Tiantian Bio and MorphoSys of Germany jointly announced that the first patient dose climbing trial in the United States for TJ210/MOR210 single-drug treatment of relapsed or incurable advanced solid tumors had been completed.
phase 1 clinical study was designed to assess the safety, toerability, pharmacodynamics and pharmacodynamics of TJ210/MOR210.
TJ210/MOR210 is an innovative monoclonal antibody for complement factor C5a subject 1 (C5aR1) in collaboration with MorphoSys.
In the tumor micro-environment on which tumor development depends, C5a acts as a key degenerative factor, recruiting myelin-based inhibitors, M2 macrophages, and neutrino granulocytes to promote tumor growth, while TJ210/MOR210 acts as an anti-tumor by blocking the activity and migration of C5aR1-positive myeloid cells.
preclinical studies have shown that TJ210/MOR210 has good anti-tumor activity in association with immuno-checkpoint inhibitors.
, in in-body studies, high C5a concentrations were also observed to block C5a/C5aR activity for long periods of time.
in non-clinical safety studies, TJ210/MOR210 showed good safety and no adverse reactions at the highest test dose.
Phase 1 clinical study of
TJ210/MOR210 in the United States was an open-label, multi-dose, multi-center dose climbing trial designed to assess its safety, tolerance and PK/PD in patients with advanced solid tumors.
the plan, the project will further conduct research on the combined treatment of TJ210/MOR210 with immuno-checkpoint inhibitors.
about TJ210/MOR210 TJ210/MOR210 is a new C5aR monoclonal antibody authorized by MorphoSys company HuCAL Platinum® technology and developed in collaboration with the company.
C5aR as a tonic factor C5a, is a potential target for cancer immunity and autoimmune disease research.
tumor cells can produce large quantities of C5a and are thought to help form immunosuppressive tumor micro-environments by recruiting and activating myelin-based inhibitory cells (MDSCs), M2 macrophages, and neutrino cells.
TJ210/MOR210 is designed to block the interaction of C5a with its receptors, potentially inhibiting the immunosuppressive function of MDSCs and enabling immune cells to attack tumors.